About this study
The goal of this study is to conduct a prospective, longitudinal study to observe the natural clinical progression and disease outcome of AS patients receiving no disease-modified intervention, with the purpose of obtaining data that will be useful for future clinical trials.
Drug
- Non intervention, Observational study
Study locations
Spain
State / region not reported
Barcelona (1)
- Hospital Parc Tauli. Servicio de Genética molecular — Recruiting
Madrid (1)
- Servicio de Farmacología Clínica. Hospital Universitario Puerta de Hierro Majadahonda — Recruiting
Contact information
- BELEN RUIZ ANTORAN, MD, Ph
+34911917479
bruizantoran@gmail.com
Full registry eligibility criteria
Inclusion Criteria: 1. Male or female between 3 months and 99 years of age. 2. Clinical diagnosis of Angelman Syndrome and molecular confirmation of the diagnosis. 3. The participant has an acceptable guardian capable of giving consent on behalf of the participant, 4. Willingness and ability of their guardians to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. Exclusion Criteria: 1. Patients with any comorbidity that, in the clinical judgment of the principal investigator, may affect the results of the study. Any confirmed chronic or acute condition or illness affecting any system(s) that could interfere with study results and/or compliance with study procedures is included. 2. Patients who are participating in parallel studies with investigational drugs. 3. Unwillingness or inability of their guardians to follow the procedures outlined in the protocol.
Important information
Registry information may change. FAST context and classifications are editorial additions. Inclusion does not confirm eligibility or availability at a specific site. Review the official record and contact the study team for participation requirements.